Last reviewed · How we verify

Flucelvax Quadrivalent Influenza Vaccine

Seqirus · Phase 2 active Biologic

Flucelvax Quadrivalent Influenza Vaccine is a Biologic drug developed by Seqirus. It is currently in Phase 2 development. Also known as: Flucelvax Quadrivalent.

At a glance

Generic nameFlucelvax Quadrivalent Influenza Vaccine
Also known asFlucelvax Quadrivalent
SponsorSeqirus
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Flucelvax Quadrivalent Influenza Vaccine

What is Flucelvax Quadrivalent Influenza Vaccine?

Flucelvax Quadrivalent Influenza Vaccine is a Biologic drug developed by Seqirus.

Who makes Flucelvax Quadrivalent Influenza Vaccine?

Flucelvax Quadrivalent Influenza Vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

Is Flucelvax Quadrivalent Influenza Vaccine also known as anything else?

Flucelvax Quadrivalent Influenza Vaccine is also known as Flucelvax Quadrivalent.

What development phase is Flucelvax Quadrivalent Influenza Vaccine in?

Flucelvax Quadrivalent Influenza Vaccine is in Phase 2.

Related